Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

Tomasz M. Beer, Sebastien J. Hotte, Fred Saad, Boris Alekseev, Vsevolod Matveev, Aude Fléchon, Gwenaelle Gravis, Florence Joly, Kim N. Chi, Zafar Malik, Brent Blumenstein, Patricia S. Stewart, Cindy A. Jacobs, Karim Fizazi

    Research output: Contribution to journalArticlepeer-review

    50 Scopus citations

    Fingerprint

    Dive into the research topics of 'Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences